INBP (Integrated Biopharma) Cyclically Adjusted FCF per Share: $0.05 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INBP Integrated Biopharma Inc INBP
36 GF Score
Price $0.16
GF Value $0.26
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Integrated Biopharma Cyclically Adjusted FCF per Share?

Integrated Biopharma INBP 36 Cyclically Adjusted FCF per Share is $0.05 as of Mar. 2026. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Integrated Biopharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.017. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.05 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Integrated Biopharma's average Cyclically Adjusted FCF Growth Rate was 25.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Integrated Biopharma was 55.00% per year. The lowest was -12.40% per year. And the median was 10.60% per year.

As of today (2026-07-31), Integrated Biopharma's current stock price is $0.16. Integrated Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $0.05. Integrated Biopharma's Cyclically Adjusted Price-to-FCF of today is 3.20.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Integrated Biopharma was 122.00. The lowest was 3.08. And the median was 8.28.


Integrated Biopharma  (OTCPK:INBP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Integrated Biopharma's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=0.16/0.05
=3.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Integrated Biopharma was 122.00. The lowest was 3.08. And the median was 8.28.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Integrated Biopharma Cyclically Adjusted FCF per Share Related Terms


Integrated Biopharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Integrated Biopharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integrated Biopharma Cyclically Adjusted FCF per Share Chart

Integrated Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.03 0.04 0.03 0.04

Integrated Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.04 0.05 0.05

INBP vs HCWC, PAVS, BABB: Cyclically Adjusted FCF per Share Comparison

For the Packaged Foods subindustry, Integrated Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrated Biopharma Cyclically Adjusted Price-to-FCF vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's Cyclically Adjusted Price-to-FCF falls into.


INBP
36GF Score
Integrated Biopharma Inc INBP
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integrated Biopharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Integrated Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.017/330.2130*330.2130
=0.017

Current CPI (Mar. 2026) = 330.2130.

Integrated Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.007 241.018 0.010
201609 -0.027 241.428 -0.037
201612 0.049 241.432 0.067
201703 0.014 243.801 0.019
201706 -0.040 244.955 -0.054
201709 0.071 246.819 0.095
201712 -0.050 246.524 -0.067
201803 0.023 249.554 0.030
201806 -0.010 251.989 -0.013
201809 0.021 252.439 0.027
201812 -0.059 251.233 -0.078
201903 0.018 254.202 0.023
201906 0.018 256.143 0.023
201909 0.053 256.759 0.068
201912 -0.022 256.974 -0.028
202003 0.079 258.115 0.101
202006 -0.070 257.797 -0.090
202009 0.059 260.280 0.075
202012 -0.025 260.474 -0.032
202103 0.035 264.877 0.044
202106 0.018 271.696 0.022
202109 0.060 274.310 0.072
202112 -0.048 278.802 -0.057
202203 0.016 287.504 0.018
202206 0.083 296.311 0.092
202209 0.031 296.808 0.034
202212 -0.003 296.797 -0.003
202303 0.046 301.836 0.050
202306 -0.040 305.109 -0.043
202309 0.043 307.789 0.046
202312 -0.061 306.746 -0.066
202403 0.042 312.332 0.044
202406 -0.010 314.175 -0.011
202409 0.020 315.301 0.021
202412 0.005 315.605 0.005
202503 0.016 319.799 0.017
202506 0.018 322.561 0.018
202509 0.036 324.800 0.037
202512 0.019 324.054 0.019
202603 0.017 330.213 0.017

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.05 mean?
Integrated Biopharma (INBP) has a Cyclically Adjusted FCF per Share of $0.05 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Integrated Biopharma and its competitors.
Is Integrated Biopharma's Cyclically Adjusted FCF per Share too high?
Integrated Biopharma's current Cyclically Adjusted FCF per Share is $0.05. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's Cyclically Adjusted FCF per Share compare to HCWC and PAVS?
Integrated Biopharma's Cyclically Adjusted FCF per Share of $0.05 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted FCF per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Integrated Biopharma and its competitors. Integrated Biopharma's current Cyclically Adjusted FCF per Share is $0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.16 — trading 38.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $0.05. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current Cyclically Adjusted FCF per Share is $0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integrated Biopharma (INBP) Overvalued in 2026?

Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued. The current stock price of $0.16 is trading 38.5% below its estimated GF Value™ of $0.26. GuruFocus considers Integrated Biopharma to be Possible Value Trap.

Key valuation signals for INBP:

  • Cyclically Adjusted FCF per Share: $0.05
  • GF Value™: $0.26 vs. price of $0.16 (38.5% below fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Integrated Biopharma Business Description

Address 225 Long Avenue, Building 15, Hillside, NJ, USA, 07205
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score

Get the complete analysis for INBP

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price
$0.26
GF Value